Interim results for the six months ended 31 January 2009

Highlights

  • Revenue of 1,933,000, representing growth of 86% for the period.
  • Profit before tax of 400,000, the first in the Group's history.
  • Deferred revenue of 3,135,000 an increase of 60% over the position last year (2008: 1,955,000).
  • Debt free with cash at bank of 1,646,000 (2008: 1,002,000).

Commenting, Nigel Brabbins, Chief Executive, said:

These results reaffirm Ultrasis' position as the leading provider of CCBT (computer delivered cognitive behavioural therapy) to the healthcare market and continue to demonstrate the company's potential for strong, profitable and sustainable growth based on a robust, renewable income stream. These results vindicate the strategy of dedicating key resource to ensure successful implementation of Beating the Blues (BTB), Ultrasis' NICE (National Institute for Health and Clinical Excellence) approved treatment for mild and moderate depression with NHS customers. While continuing to focus on utilisation of BTB across the NHS and widening its applications, we will further extend our retail offering with additional products and services through The Wellness Shop portal. We will also focus increasingly on growing the market internationally for these and our core product, Beating the Blues.

The full interim results for the six months ended 31st January 2009 document.

Further information:

Nigel Brabbins
CEO
E-Mail: ultrasis@ultrasis.com
Telephone: +44 (0) 20 7566 3900
Fax: +44 (0) 20 7253 5313

Geoff Nash
FinnCap
Nominated Adviser and Joint Broker
Telephone: +44 (0) 20 7600 1658

John Webb
Marshall Securities
Joint Broker
Telephone: +44 (0) 207 490 3788

Karen White/Sarah Rice
JBP Public Relations
Telephone: +44 (0) 117 9073400

News Categories

RSS Feed

Latest News

Register for Updates

Never miss Ultrasis news by registering for updates.